Biogen Inc. said on November 9 the company was investigating the death of a 75-year-old patient who had taken the newly approved Alzheimer’s drug Aduhelm, adding that it was not yet known whether the death was related to the treatment.
Eli Lilly and Co. on March 14 said the company’s experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32 percent compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.
A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.
Nearly 20 percent of American adolescents, or one in five, has suffered a concussion, according to newly released statistics.
Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.